Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2021

Hoth Therapeutics and UCRI to perform critical studies for HT-006 antibiotic

Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.

Hoth Therapeutics and the University of Cincinnati Research Institute (UCRI) in the US have signed a research agreement to conduct critical antimicrobial characterisation studies for the streamlined development of the antibiotic HT-006.

HT-006 is a new molecular entity (NME) developed by the Walter Reed Army Institute of Research (WRAIR) using a novel antibacterial action mechanism that targets multiple bacterial pathogens.

It is currently under development as a potential treatment for multi-drug resistant bacterial infections of lung-like hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and ventilator-associated pneumonia (VAP).

The company earlier licensed the technology from the WRAIR for commercial evaluation.

The new research programme is led by the University of Cincinnati (UC) College of Medicine, Department of Molecular Genetics, Biochemistry and Microbiology professor Daniel Hassett.

Hoth Therapeutics CEO Robb Knie said: “We are pleased to commence a new research programme with Dr Hassett and the University of Cincinnati Research Institute (UCRI).

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

“There is a growing need for new antibiotic therapies targeted at multi-drug resistant bacteria, particularly for life-threatening conditions like hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP).

“The work to be conducted by Dr Hassett will assist in expediting the HT-006 drug development programme towards the clinic.”

The research will focus on studying pathogenic mechanisms of multi-drug resistant bacteria and effective antimicrobial strategies to fight these organisms.

This plan includes critical antimicrobial in vitro characterisation studies for the novel antibiotic HT-006 in alignment with the US Food and Drug Administration (FDA) programme for antibacterial therapies.

Hoth Therapeutics stated that, through this streamlined programme, nonclinical animal studies will be used to reduce clinical studies required for approval.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU